Merus NV surges after cancer combo-therapy succeeds in mid-stage trial

Merus NV

23/05/2025 17:22

** U.S.-listed shares of Dutch drugmaker Merus NV MRUS.O  surge 32% to $54.93

** Late on Thursday, Merus' lead drug candidate petosemtamab in combination with Merck's MRK.N Keytruda delayed progression of a type of head and neck cancer in a mid-stage trial

** The combination treatment showed a 79% survival rate after 1 year in a group of 43 patients

** Including session's moves, MRUS stock up 29.6% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))